Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron

Mungli Prakash, Sharmila Upadhya, Ravindra Prabhu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Non-transferrin bound iron (NTBI) has been found to be raised in end stage renal disease (ESRD) patients on hemodialysis (HD) receiving intravenous (IV) iron. Such NTBI is proposed to cause oxidative damage to biomolecules. Method: NTBI, both ferrous (Fe+2) and ferric (Fe +3) forms, serum ferritin, protein thiols and lipid hydroperoxides were estimated by spectrophotometric and electrochemiluminescence immunoassay methods in patients with chronic renal failure (CRF), patients with ESRD on HD not receiving IV iron, and in normal controls. Results: NTBI (Fe+2) in HD patients not receiving IV iron was higher than in normal controls. NTBI (Fe+3) was significantly higher in HD patients not on IV iron therapy than in CRF and normal controls. There was no significant increase in NTBI in CRF patients when compared to normal controls. Serum ferritin was higher in HD patients compared to CRF and normal controls. There was a significant increase in lipid hydroperoxides and protein thiols in HD patients and CRF patients when compared to normal controls. The NTBI did not correlate with serum ferritin and oxidative markers. Conclusion: The source of NTBI in hemodialysis is not only IV iron therapy but also the hemodialysis procedure per se. It may be due to microhemolysis during hemodialysis. The NTBI is however found to be catalytically inactive.

Original languageEnglish
Pages (from-to)194-198
Number of pages5
JournalClinica Chimica Acta
Volume360
Issue number1-2
DOIs
Publication statusPublished - 01-10-2005

Fingerprint

Renal Dialysis
Iron
Serum
Chronic Kidney Failure
Ferritins
Lipid Peroxides
Sulfhydryl Compounds
Biomolecules
Immunoassay
Blood Proteins
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Prakash, Mungli ; Upadhya, Sharmila ; Prabhu, Ravindra. / Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. In: Clinica Chimica Acta. 2005 ; Vol. 360, No. 1-2. pp. 194-198.
@article{c4e6669d36a74c588996d054c4256e81,
title = "Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron",
abstract = "Background: Non-transferrin bound iron (NTBI) has been found to be raised in end stage renal disease (ESRD) patients on hemodialysis (HD) receiving intravenous (IV) iron. Such NTBI is proposed to cause oxidative damage to biomolecules. Method: NTBI, both ferrous (Fe+2) and ferric (Fe +3) forms, serum ferritin, protein thiols and lipid hydroperoxides were estimated by spectrophotometric and electrochemiluminescence immunoassay methods in patients with chronic renal failure (CRF), patients with ESRD on HD not receiving IV iron, and in normal controls. Results: NTBI (Fe+2) in HD patients not receiving IV iron was higher than in normal controls. NTBI (Fe+3) was significantly higher in HD patients not on IV iron therapy than in CRF and normal controls. There was no significant increase in NTBI in CRF patients when compared to normal controls. Serum ferritin was higher in HD patients compared to CRF and normal controls. There was a significant increase in lipid hydroperoxides and protein thiols in HD patients and CRF patients when compared to normal controls. The NTBI did not correlate with serum ferritin and oxidative markers. Conclusion: The source of NTBI in hemodialysis is not only IV iron therapy but also the hemodialysis procedure per se. It may be due to microhemolysis during hemodialysis. The NTBI is however found to be catalytically inactive.",
author = "Mungli Prakash and Sharmila Upadhya and Ravindra Prabhu",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.cccn.2005.04.024",
language = "English",
volume = "360",
pages = "194--198",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. / Prakash, Mungli; Upadhya, Sharmila; Prabhu, Ravindra.

In: Clinica Chimica Acta, Vol. 360, No. 1-2, 01.10.2005, p. 194-198.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron

AU - Prakash, Mungli

AU - Upadhya, Sharmila

AU - Prabhu, Ravindra

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Background: Non-transferrin bound iron (NTBI) has been found to be raised in end stage renal disease (ESRD) patients on hemodialysis (HD) receiving intravenous (IV) iron. Such NTBI is proposed to cause oxidative damage to biomolecules. Method: NTBI, both ferrous (Fe+2) and ferric (Fe +3) forms, serum ferritin, protein thiols and lipid hydroperoxides were estimated by spectrophotometric and electrochemiluminescence immunoassay methods in patients with chronic renal failure (CRF), patients with ESRD on HD not receiving IV iron, and in normal controls. Results: NTBI (Fe+2) in HD patients not receiving IV iron was higher than in normal controls. NTBI (Fe+3) was significantly higher in HD patients not on IV iron therapy than in CRF and normal controls. There was no significant increase in NTBI in CRF patients when compared to normal controls. Serum ferritin was higher in HD patients compared to CRF and normal controls. There was a significant increase in lipid hydroperoxides and protein thiols in HD patients and CRF patients when compared to normal controls. The NTBI did not correlate with serum ferritin and oxidative markers. Conclusion: The source of NTBI in hemodialysis is not only IV iron therapy but also the hemodialysis procedure per se. It may be due to microhemolysis during hemodialysis. The NTBI is however found to be catalytically inactive.

AB - Background: Non-transferrin bound iron (NTBI) has been found to be raised in end stage renal disease (ESRD) patients on hemodialysis (HD) receiving intravenous (IV) iron. Such NTBI is proposed to cause oxidative damage to biomolecules. Method: NTBI, both ferrous (Fe+2) and ferric (Fe +3) forms, serum ferritin, protein thiols and lipid hydroperoxides were estimated by spectrophotometric and electrochemiluminescence immunoassay methods in patients with chronic renal failure (CRF), patients with ESRD on HD not receiving IV iron, and in normal controls. Results: NTBI (Fe+2) in HD patients not receiving IV iron was higher than in normal controls. NTBI (Fe+3) was significantly higher in HD patients not on IV iron therapy than in CRF and normal controls. There was no significant increase in NTBI in CRF patients when compared to normal controls. Serum ferritin was higher in HD patients compared to CRF and normal controls. There was a significant increase in lipid hydroperoxides and protein thiols in HD patients and CRF patients when compared to normal controls. The NTBI did not correlate with serum ferritin and oxidative markers. Conclusion: The source of NTBI in hemodialysis is not only IV iron therapy but also the hemodialysis procedure per se. It may be due to microhemolysis during hemodialysis. The NTBI is however found to be catalytically inactive.

UR - http://www.scopus.com/inward/record.url?scp=24044545558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044545558&partnerID=8YFLogxK

U2 - 10.1016/j.cccn.2005.04.024

DO - 10.1016/j.cccn.2005.04.024

M3 - Article

C2 - 15979061

AN - SCOPUS:24044545558

VL - 360

SP - 194

EP - 198

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -